Eligo Bioscience | Series BDec 2023$30M | $48M |
| Co-investors: Samir Kaul (Khosla Ventures) |
QurAlis | Series BMar 2023$88M | $140M |
| Co-investors: Amy Schulman (Polaris Partners), Roel Bulthuis (INKEF Capital), Johannes Fruehauf (Mission BioCapital), Philip Scheltens (EQT Life Sciences), Cillian King (EQT Life Sciences), Jeffrey Moore (MP Healthcare Venture Management), Stephen Thompson (Brandon Capital Partners) |
OMass Therapeutics | Series BApr 2022$95M | $95M |
| Co-investors: Scott Biller (GV (Google Ventures)), Diana Bernstein (Northpond Ventures) |
Lava Therapeutics | Series C Sep 2020 $83M  | $100M |
| Co-investors: Guido Magni (Versant Ventures), Nanna Luneborg (Forbion), Joël Jean-Mairet (Ysios Capital) |
Inbiomotion | Series BMar 2016$2M Series AJun 2012$2M | $4M |
| Co-investors: Joël Jean-Mairet (Ysios Capital), Jose Mesa (Alta Life Sciences) |
Minoryx Therapeutics | Series AOct 2015$22M | $81M |
| Co-investors: Carlos Esteban (Faber), Pablo Cironi (Caixa Capital), Thierry Laugel (Kurma Partners), Monique Schiersing (Roche Venture Fund) |
AM Pharma | Series ESep 2014$16M Series DSep 2011$40M | $210M |
| Co-investors: Raphael Wisniewski (Andera Partners), Geert-Jan Mulder (Forbion), Rémi Droller (Kurma Partners), Joël Jean-Mairet (Ysios Capital), Martijn Kleijwegt (EQT Life Sciences), Felice Verduyn - van Weegen (EQT Life Sciences) |